Abstract
Mitomycin C is an antibiotic alkylating agent isolated from the fermentation of Streptomyces caespitosus in 1958. Clinical trials were initiated in Japan soon after the demonstration of antitumor activity against a broad spectrum of transplanted animal tumours [2]. Mitomycin C was reported to have a high degree of efficacy for human cancer, which prompted a cooperative multiinstitution evaluation of this agent in the United States. A preliminary summary of the results of the initial experience was reported in 1959 by Jones [11]. Of 120 patients treated, objective responses were observed in 21 (18.5%) including breast cancer, Hodgkin’s disease, lymphocytic lymphoma and chronic granulocytic leukemia. Treatment was discontinued in 87% of patients because of severe hematologic toxicity. It was concluded that mitomycin C had an extremely narrow therapeutic index, while demonstrating only limited efficacy. The result was a sharply reduced interest for mitomycin C as an anticancer agent in the United States.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Baker, L. H., Caoili, E. M., Izbicki, R. M., Opipari, M. I., Vaitkevicius, V. K.: A comparative study of mitomycin C and porfiromycin. Proc. Am. Soc. Clin. Oncol. 15, 182(1974).
Carter, S. K.: Mitomycin C (NSC-26980) clinical brochure. Cancer Chemother. Rep., part 3 1, 99–114(1968).
Comis, R. L., Carter, S. K.: Integration of chemotherapy into combined modality treatment of solid tumors III. Gastric cancer. Cancer Treat. Rev. 1, 221–238 (1974).
Crooke, S. T., Bradner, W. T.: Mitomycin C.: A review. Cancer Treat. Rev. 3, 121 139, 1976.
Dejager, R. L., Magill, G. B., Golbey, R. B., Krakoff, I. H.: Combination chemotherapy with mitomycin C, 5-fluorouracil, and cytosine arabinoside in gastrointestinal cancer. Cancer Treat. Rep. 60,1373–1375(1976).
Ferguson, D., Humphrey, E.: Mitomycin C. Cancer Chemother. Rep. 8, 154 (1960).
Frank, W., Osterberg, A. E.: Mitomycin C (NSC-26980), an evaluation of Japanese reports. Cancer Chemother. Rep. 9, 114–119 (1960).
Godfrey, T. E., Wilbur, D. W.: Clinical experience with mitomycin C in large infrequent doses. Cancer 29, 1647–1652(1972).
Horton, J., Olson, K. B., Gehrt, P., Spear, M.: Combination therapy with 5-fluorouracil (NSC-19893), mitomycin (NSC-26980), vincristine (NSC-67574), and thioTEPA (NSC-6396) for advanced cancer. Cancer Chemother. Rep. 49, 59–61 (1965).
Hoshino, A., Kato, T., Amo, H., et al.: Combination chemotherapy of mitomycin C, 5-fluorouracil and cytosine arabinoside in L-1210 mouse leukemia. In: Proceedings of the 10th International Cancer Congress, Houston, Texas. Houston: Medical Arts Publishing Co. 1970, pp 409–410.
Jones, R. Jr.: Mitomycin C. A preliminary report of studies of human pharmacology and initial therapeutic trial. Cancer Chemother. Rep. 2, 3–7 (1959).
Liu, K., Mittleman, A., Sproul, E. E., Elias, E. G.: Renal toxicity in man treated with mitomyein-C. Cancer 28, 1314–1320(1971).
Macdonald, J., Schein, P., Ueno, W., Woolley, P.: 5-Fluorouracil, mitomycin C, and adriamycin—F AM: A new combination chemotherapy program for advanced gastric carcinoma. Proc. Am. Soc. Clin. Onc. 17, 264 (1976).
Manheiner, L. H., Vital, J.: Mitomycin-C in the therapy of far-advanced malignant tumors. Cancer 19, 207–212 (1966).
Moertel, C. G., Reitemeier, R. J., Hahn, R. G.: Mitomycin C therapy in advanced gastrointestinal cancer. J. Am. Med. Assoc. 204, 1045–1048 (1968).
Moore, G. E., Boss, I. D. J., Ausman, R., Nadler, S., Jones, R., Jr., Slack, N., Rimm, A. A.: Effects of mitomycin C. (NSC-26980) in 346 patients with advanced cancer. Eastern clinical drug evaluation program. Cancer Chemother. Rep. 52, 657–684 (1968).
Ota, K., Kurita, S., Nishimura, M., et al.: Combination therapy with mitomycin-C (NSC-26980), 5-fluorouracil (NSC-19883), and cytosine arabinoside (NSC-63878) for advanced cancer in man. Cancer Chemotherap. Rep. 56, 373–385 (1972).
Ratanatharathorn, V., Cadnapaphorndai, P., Rosenberg, B., Baker, L. H., Taber, S., Ruffer, B. W., Mcdonald, F. D., Vaitkevicius, V. K.: Clinicai and pathologic study of mitomycin-C nephrotoxicity: A retrospective analysis. Proc. Am. Soc. Clin. Oncology 18, 293 (1977).
Reitemeier, R. J., Moertel, C. G., Hahn, R. G.: Combination chemotherapy in gastrointestinal cancer. Cancer Chemother. Rep. 30, 1425–1428 (1970).
Wiggans, G., Smythe, T., Ueno, W., Macdonald, J., Schein, P., Flannery, E.: Streptozotocin, mitomycin, and 5-fluorouracil, SMF, chemotherapy for advanced pancreatic carcinoma: Phase II trial. Cancer (In Press).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1978 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Schein, P.S., MacDonald, J.S., Hoth, D., Woolley, P.V. (1978). Mitomycin C: Experience in the United States, with Emphasis on Gastric Cancer. In: Carter, S.K., Umezawa, H., Douros, J., Sakurai, Y. (eds) Antitumor Antibiotics. Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer, vol 63. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81219-4_14
Download citation
DOI: https://doi.org/10.1007/978-3-642-81219-4_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81221-7
Online ISBN: 978-3-642-81219-4
eBook Packages: Springer Book Archive